• Head-to-head clinical trials of IL-23p19 subunit inhibitors versus other biologics for IBD have not been conducted; thus, more clinical evidence is warranted to support the efficacy of IL-23p19 subunit inhibitors compared to other agents in the same class or in other classes. Here, IL23A is linked to inflammatory bowel disease.